Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03190967
Title T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Recruitment Recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Her2-receptor positive breast cancer

Therapies

Ado-trastuzumab emtansine

Ado-trastuzumab emtansine + Temozolomide

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.